Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-(5-isoquinolinesulfonyl)homopiperazine
2. At 877
3. At-877
4. At877
5. Fasudil
6. Fasudil Mesylate
7. Ha 1077
8. Ha-1077
1. 105628-07-7
2. Fasudil Hcl
3. Eril
4. Fasudil (ha-1077) Hcl
5. 5-((1,4-diazepan-1-yl)sulfonyl)isoquinoline Hydrochloride
6. Fasudil (hydrochloride)
7. At-877
8. Fasudil Monohydrochloride
9. Ha-1077
10. Sq04n8s7br
11. Fasudil, Monohydrochloride Salt
12. 105628-07-7 (hcl)
13. 1h-1,4-diazepine, Hexahydro-1-(5-isoquinolinylsulfonyl)-, Monohydrochloride
14. Dsstox_cid_25615
15. Dsstox_rid_81004
16. Dsstox_gsid_45615
17. Fasudil Hydrochloride (jan)
18. 1-(5-isoquinolinesulfonyl)homopiperazine Hydrochloride
19. Chembl541388
20. Ha-1077 Hydrochloride
21. 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline;hydrochloride
22. 5-((1,4-diazepan-1-yl)sulfonyl)isoquinoline Xhydrochloride
23. At 877 Hydrochloride
24. Fasudil Hydrochloride [jan]
25. Ha 1077 Hydrochloride
26. Ha-1077 Dihydrochloride
27. 133337-43-6
28. Cas-105628-07-7
29. Ncgc00018100-04
30. Unii-sq04n8s7br
31. C14h17n3o2s.hcl
32. Fasdil
33. Fasudil-ha
34. Calciumcyclamate
35. Fasudil, Monohcl
36. Hexahydro-1-(5-isoquinolinylsulfonyl)-1h-1,4-diazepine Monohydrochloride
37. Regid_for_cid_4917
38. Bmk1-e2
39. Mls000069344
40. Schembl317082
41. Fasudil Hcl (ha-1077)
42. Fasudil Hcl - Ha-1077
43. 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline Hydrochloride
44. Dtxsid1045615
45. Regid_for_cid_163751
46. Chebi:31593
47. Fasudil Hydrochloride [mi]
48. Act06296
49. Bcp26351
50. Tox21_110824
51. Mfcd00943198
52. S1573
53. Fasudil Hydrochloride [mart.]
54. Akos015897321
55. Fasudil Hydrochloride [who-dd]
56. Tox21_110824_1
57. Ac-4515
58. Ccg-267783
59. Cs-0225
60. Ncgc00018100-08
61. Ncgc00180915-01
62. 111ge018
63. As-17751
64. Hy-10341
65. Smr000058993
66. Am20050635
67. F0839
68. Ft-0631034
69. Sw218155-2
70. A21128
71. D01840
72. 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline Hcl
73. Sr-01000000005
74. 1-(5isoquinolinesulfonyl)homopiperazine Hydrochloride
75. Sr-01000000005-2
76. Q27289337
77. 1-(5-isoquinolinesulfonyl)homopiperazine Dihydrochloride
78. 5-(1-homopiperazinyl)sulfonylisoquinoline Hydrochloride
79. 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline;hydron;chloride
80. 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline Hydrochloride (1:1)
81. 5-(hexahydro-1h-1,4-diazepine-1-ylsulfonyl)isoquinoline Hydrochloride
82. Isoquinoline, 5-((hexahydro-1h-1,4-diazepin-1-yl)sulfonyl)-, Hydrochloride (1:1)
| Molecular Weight | 327.8 g/mol |
|---|---|
| Molecular Formula | C14H18ClN3O2S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 327.0808257 g/mol |
| Monoisotopic Mass | 327.0808257 g/mol |
| Topological Polar Surface Area | 70.7 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 421 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of non-traumatic subarachnoid haemorrhage
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26740
Submission : 2013-02-01
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over ...

About the Company : Lunan Pharmaceutical Group is an integrated pharmaceutical group setting production, scientific research and sale of traditional Chinese medicines, chemicals, biological products i...

About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...

About the Company : Suzhou Lixin Pharmaceutical Co., Ltd. has focused on developing high-quality APIs and advanced intermediates for global markets. Specializing in anti-tumor, cardiovascular, antivir...

About the Company : Wanbang Biopharmaceuticals is a leading anti-diabetic pharmaceutical company in China and a core member of Fosun Group (SH600196; HK02196). Wanbang Biopharma has been focusing at t...

About the Company : Yangtze River Pharmaceutical Group (hereinafter refers to YRPG) was founded in 1971, with over 9000 employees. Comprehensive competitiveness of YRPG has been ranked in the top five...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Bravyl (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Fasudil,Inapplicable
Therapeutic Area: Neurology Brand Name: Bravyl
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2024

Woolsey Pharmaceuticals Completes Patient Recruitment for High-Dose Cohort of ALS Study
Details : Bravyl (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : Bravyl
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Bravyl (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), given orally, is being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Fasudil,Inapplicable
Therapeutic Area: Neurology Brand Name: Bravyl
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2024

Woolsey Pharmaceuticals Treats First ALS Patient with Higher-Dose BRAVYL in REAL Study
Details : Bravyl (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), given orally, is being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : Bravyl
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RT1968 (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Fasudil,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024

Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Details : RT1968 (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fasudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Fasudil,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 01, 2022

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
Details : Fasudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fasudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dementia.
Lead Product(s): Fasudil,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2021

Fasudil fOr redUcing elopemeNt and Spatial Disorientation
Details : Fasudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fasudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Lead Product(s): Fasudil,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 02, 2021

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
Details : Fasudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
47
PharmaCompass offers a list of Fasudil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fasudil manufacturer or Fasudil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fasudil manufacturer or Fasudil supplier.
A Fasudil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fasudil, including repackagers and relabelers. The FDA regulates Fasudil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fasudil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fasudil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Fasudil supplier is an individual or a company that provides Fasudil active pharmaceutical ingredient (API) or Fasudil finished formulations upon request. The Fasudil suppliers may include Fasudil API manufacturers, exporters, distributors and traders.
click here to find a list of Fasudil suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Fasudil DMF (Drug Master File) is a document detailing the whole manufacturing process of Fasudil active pharmaceutical ingredient (API) in detail. Different forms of Fasudil DMFs exist exist since differing nations have different regulations, such as Fasudil USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fasudil DMF submitted to regulatory agencies in the US is known as a USDMF. Fasudil USDMF includes data on Fasudil's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fasudil USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fasudil suppliers with USDMF on PharmaCompass.
Fasudil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fasudil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fasudil GMP manufacturer or Fasudil GMP API supplier for your needs.
A Fasudil CoA (Certificate of Analysis) is a formal document that attests to Fasudil's compliance with Fasudil specifications and serves as a tool for batch-level quality control.
Fasudil CoA mostly includes findings from lab analyses of a specific batch. For each Fasudil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fasudil may be tested according to a variety of international standards, such as European Pharmacopoeia (Fasudil EP), Fasudil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fasudil USP).